Dynavax To Seek Experienced Vaccines Partner To Commercialize Heplisav
The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.
The company reports positive Phase III data for the hepatitis B vaccine showing 98.5% seroprotection after two doses.